Phase II trial of cyclophosphamide, hexamethylmelamine, adriamycin, and cis-dichlorodiammineplatinum(II) combination chemotherapy in advanced ovarian carcinoma

R. Kane, H. Harvey, T. Andrews, A. Bernath, S. Curry, R. Dixon, R. Gottlieb, M. Kukrika, A. Lipton, R. Mortel, J. Ricci, D. White

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

A monthly four-drug regimen of cyclophosphamide, adriamycin, and cis-dichlorodiammineplatinum(II), each given iv on Day 1, and hexamethylmelamine, given orally on Days 1-14 (CHAP), was administered to 39 women with advanced epithelial ovarian carcinoma who had previously failed alkylating agent therapy. Of 35 evaluable patients with a measurable disease parameter, seven (20%) achieved a clinical complete response and ten (29%) achieved a clinical partial response. The median duration of complete response is >9 months and the median duration of partial response is 4 months. Ninety percent of the patients required dose adjustments because of profound leukopenia, thrombocytopenia, or gastrointestinal intolerance. CHAP is an active but toxic regimen in the management of advanced ovarian cancer. The toxicity encountered reflected the intensity of the drug schedule as well as the combined influences of advanced stage of disease, poor nutritional and performance status, and prior therapy. The efficacy of this CHAP regimen warrants a controlled trial compared to other active drug programs.

Original languageEnglish (US)
Pages (from-to)307-339
Number of pages33
JournalCancer Treatment Reports
Volume63
Issue number2
StatePublished - Dec 1 1979

Fingerprint

Altretamine
Combination Drug Therapy
Doxorubicin
Cyclophosphamide
Cisplatin
Carcinoma
Pharmaceutical Preparations
Poisons
Alkylating Agents
Leukopenia
Nutritional Status
Thrombocytopenia
Ovarian Neoplasms
Appointments and Schedules
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Kane, R. ; Harvey, H. ; Andrews, T. ; Bernath, A. ; Curry, S. ; Dixon, R. ; Gottlieb, R. ; Kukrika, M. ; Lipton, A. ; Mortel, R. ; Ricci, J. ; White, D. / Phase II trial of cyclophosphamide, hexamethylmelamine, adriamycin, and cis-dichlorodiammineplatinum(II) combination chemotherapy in advanced ovarian carcinoma. In: Cancer Treatment Reports. 1979 ; Vol. 63, No. 2. pp. 307-339.
@article{19ec18cd88f44fa9a4a8a7e08ac4c99c,
title = "Phase II trial of cyclophosphamide, hexamethylmelamine, adriamycin, and cis-dichlorodiammineplatinum(II) combination chemotherapy in advanced ovarian carcinoma",
abstract = "A monthly four-drug regimen of cyclophosphamide, adriamycin, and cis-dichlorodiammineplatinum(II), each given iv on Day 1, and hexamethylmelamine, given orally on Days 1-14 (CHAP), was administered to 39 women with advanced epithelial ovarian carcinoma who had previously failed alkylating agent therapy. Of 35 evaluable patients with a measurable disease parameter, seven (20{\%}) achieved a clinical complete response and ten (29{\%}) achieved a clinical partial response. The median duration of complete response is >9 months and the median duration of partial response is 4 months. Ninety percent of the patients required dose adjustments because of profound leukopenia, thrombocytopenia, or gastrointestinal intolerance. CHAP is an active but toxic regimen in the management of advanced ovarian cancer. The toxicity encountered reflected the intensity of the drug schedule as well as the combined influences of advanced stage of disease, poor nutritional and performance status, and prior therapy. The efficacy of this CHAP regimen warrants a controlled trial compared to other active drug programs.",
author = "R. Kane and H. Harvey and T. Andrews and A. Bernath and S. Curry and R. Dixon and R. Gottlieb and M. Kukrika and A. Lipton and R. Mortel and J. Ricci and D. White",
year = "1979",
month = "12",
day = "1",
language = "English (US)",
volume = "63",
pages = "307--339",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "2",

}

Kane, R, Harvey, H, Andrews, T, Bernath, A, Curry, S, Dixon, R, Gottlieb, R, Kukrika, M, Lipton, A, Mortel, R, Ricci, J & White, D 1979, 'Phase II trial of cyclophosphamide, hexamethylmelamine, adriamycin, and cis-dichlorodiammineplatinum(II) combination chemotherapy in advanced ovarian carcinoma', Cancer Treatment Reports, vol. 63, no. 2, pp. 307-339.

Phase II trial of cyclophosphamide, hexamethylmelamine, adriamycin, and cis-dichlorodiammineplatinum(II) combination chemotherapy in advanced ovarian carcinoma. / Kane, R.; Harvey, H.; Andrews, T.; Bernath, A.; Curry, S.; Dixon, R.; Gottlieb, R.; Kukrika, M.; Lipton, A.; Mortel, R.; Ricci, J.; White, D.

In: Cancer Treatment Reports, Vol. 63, No. 2, 01.12.1979, p. 307-339.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Phase II trial of cyclophosphamide, hexamethylmelamine, adriamycin, and cis-dichlorodiammineplatinum(II) combination chemotherapy in advanced ovarian carcinoma

AU - Kane, R.

AU - Harvey, H.

AU - Andrews, T.

AU - Bernath, A.

AU - Curry, S.

AU - Dixon, R.

AU - Gottlieb, R.

AU - Kukrika, M.

AU - Lipton, A.

AU - Mortel, R.

AU - Ricci, J.

AU - White, D.

PY - 1979/12/1

Y1 - 1979/12/1

N2 - A monthly four-drug regimen of cyclophosphamide, adriamycin, and cis-dichlorodiammineplatinum(II), each given iv on Day 1, and hexamethylmelamine, given orally on Days 1-14 (CHAP), was administered to 39 women with advanced epithelial ovarian carcinoma who had previously failed alkylating agent therapy. Of 35 evaluable patients with a measurable disease parameter, seven (20%) achieved a clinical complete response and ten (29%) achieved a clinical partial response. The median duration of complete response is >9 months and the median duration of partial response is 4 months. Ninety percent of the patients required dose adjustments because of profound leukopenia, thrombocytopenia, or gastrointestinal intolerance. CHAP is an active but toxic regimen in the management of advanced ovarian cancer. The toxicity encountered reflected the intensity of the drug schedule as well as the combined influences of advanced stage of disease, poor nutritional and performance status, and prior therapy. The efficacy of this CHAP regimen warrants a controlled trial compared to other active drug programs.

AB - A monthly four-drug regimen of cyclophosphamide, adriamycin, and cis-dichlorodiammineplatinum(II), each given iv on Day 1, and hexamethylmelamine, given orally on Days 1-14 (CHAP), was administered to 39 women with advanced epithelial ovarian carcinoma who had previously failed alkylating agent therapy. Of 35 evaluable patients with a measurable disease parameter, seven (20%) achieved a clinical complete response and ten (29%) achieved a clinical partial response. The median duration of complete response is >9 months and the median duration of partial response is 4 months. Ninety percent of the patients required dose adjustments because of profound leukopenia, thrombocytopenia, or gastrointestinal intolerance. CHAP is an active but toxic regimen in the management of advanced ovarian cancer. The toxicity encountered reflected the intensity of the drug schedule as well as the combined influences of advanced stage of disease, poor nutritional and performance status, and prior therapy. The efficacy of this CHAP regimen warrants a controlled trial compared to other active drug programs.

UR - http://www.scopus.com/inward/record.url?scp=0018772679&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018772679&partnerID=8YFLogxK

M3 - Article

C2 - 109201

AN - SCOPUS:0018772679

VL - 63

SP - 307

EP - 339

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 2

ER -